| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $14.4M | — | -6.5% |
| SG&A Expense | $5.3M | — | +5.7% |
| Operating Income | -$19.7M | — | +3.5% |
| Net Income | -$17.6M | — | +0.4% |
| EPS (Basic) | -$0.29 | — | +6.5% |
| EPS (Diluted) | -$0.29 | — | +6.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $12.8M | -24.2% | -6.6% |
| Short-term Investments | $210.1M | +3.5% | -2.8% |
| Current Assets | $227.0M | +1.5% | -2.8% |
| Total Assets | $230.4M | +1.9% | -3.0% |
| Current Liabilities | $10.2M | -21.9% | +23.7% |
| Total Liabilities | $12.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$16.4M | — | +2.1% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | -$7.6M | — | -196.4% |
| Financing Cash Flow | $19.9M | — | — |
| Free Cash Flow | -$16.4M | — | +2.6% |
| +29.6% |
| Stockholders' Equity | $218.1M | +2.6% | -4.3% |